- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01075737
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
Observational Study to Assess the Quality of Life of the Caregivers of Patients With Multiple Sclerosis
Study Overview
Status
Conditions
Detailed Description
Caregivers of subjects diagnosed with MS have to take care of many activities of MS subjects that they cannot perform themselves, because of their lack of autonomy. The fact of aiding a person with some degree of disability due to a chronic disease in an intense way and for a long time could generate a high level of satisfaction in the caregiver; but at the same time the emotional and physical exhaustion of the caregiver increases as the disease progresses. The QoL of the person who is emotionally bonded to the MS subject as a caregiver has a great chance to be affected; and this is for sure more likely than in the case when the caregiver is a hired professional.
OBJECTIVES
Primary objective:
- To identify the impact of MS on the QoL of the MS subjects and their caregivers
Secondary objectives:
- To establish the correlation between the QoL of the subjects with MS and their caregivers
- To identify the predictors of the QoL in the caregiver group
This is an observational, prospective and non-interventional study planned to be conducted in 20 centers in Argentina. The subjects with diagnosed MS will be managed with the clinical and therapeutic elements that their treating doctors considered appropriate, without modifying their decisions due to the subjects' inclusion into the study. The caregivers will be asked to complete the QoL questionnaire as a part of the normal interview on each and every visit. The total duration of the study is 24 months. A descriptive analysis will be performed for the demographic and clinical characteristics of the investigation subjects, as well as for the characteristics of the treatments they receive when they start their participation in this study. For the qualitative variables, treatment modifications, frequency tables and the percentages will be performed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Santiago del Estero, Argentina, G4200AWD
- 25 de Mayo 138, Capital, Pcia. de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- MS subjects and their caregivers, >21 years of age of both sexes
- Subjects who have signed informed consent
- Subjects with established MS diagnosis according to the revised Mc Donald criteria - 2005 with at least 1 year of evolution
- Subjects with MS that have an identified caregiver
Exclusion Criteria:
- Subjects with other(s) associated neurological, psychiatric or systemic disease(s)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Subjects with Multiple Sclerosis
Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
|
|
Caregivers
Caregivers (aged >21 years) for MS subjects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of MS on QoL of subjects diagnosed with multiple sclerosis (MS) and their caregivers
Time Frame: Each visit starting from the initial visit (Day 0) to end of the observation period (i.e. 24 months)
|
SF-36 will be administered to subjects diagnosed with MS and their caregivers; Beck depression inventory and MS-Functional system scores to subjects diagnosed with MS.
|
Each visit starting from the initial visit (Day 0) to end of the observation period (i.e. 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation between QoL of subjects with MS and their caregivers
Time Frame: During the observation period of 24 months starting from the initial visit (i.e. Day 0)
|
During the observation period of 24 months starting from the initial visit (i.e. Day 0)
|
|
Predictors of QoL of caregivers
Time Frame: During the observation period of 24 months starting from the initial visit (i.e. Day 0)
|
During the observation period of 24 months starting from the initial visit (i.e. Day 0)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Miguel Jacobo, Neurologist, 25 de Mayo 138 (Capital, Pcia. de Santiago del Estero) G4200AWD
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200077-501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States